Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus: Ten of 11 analysts recommend buying Oruka Therapeutics, while one rates it a sell. The average 12-month price target is $134.30, with targets ranging from $120 to $165.
• Shares have surged: ORKA opened at $113.08, near its 52-week high of $113.31, compared with a 52-week low of $14.08. The company has a market capitalization of approximately $7.49 billion.
• Earnings and insider activity remain notable: Oruka reported a quarterly loss of $0.55 per share, missing the $0.51 consensus estimate, while insiders sold $12.8 million of stock during the last quarter, primarily to cover tax obligations on vested equity awards.

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) has received an average recommendation of "Moderate Buy" from the eleven analysts that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and ten have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $134.30.

A number of equities research analysts have commented on ORKA shares. HC Wainwright reissued a "buy" rating and set a $120.00 price objective on shares of Oruka Therapeutics in a report on Monday, August 3rd. Wall Street Zen downgraded shares of Oruka Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday. Wedbush reiterated an "outperform" rating and set a $165.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Barclays increased their price target on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the company an "overweight" rating in a research note on Monday, April 27th. Finally, Leerink Partners set a $120.00 price target on shares of Oruka Therapeutics in a report on Thursday, April 30th.

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock opened at $113.08 on Wednesday. The business's fifty day moving average is $89.42 and its two-hundred day moving average is $63.91. The firm has a market cap of $7.49 billion, a P/E ratio of -55.70 and a beta of -0.34. Oruka Therapeutics has a 52 week low of $14.08 and a 52 week high of $113.31.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). On average, equities research analysts predict that Oruka Therapeutics will post -2.27 earnings per share for the current year.

Insider Transactions at Oruka Therapeutics

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,947 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $69.28, for a total value of $550,568.16. Following the transaction, the insider directly owned 32,718 shares in the company, valued at approximately $2,266,703.04. This trade represents a 19.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock in a transaction on Monday, June 15th. The shares were sold at an average price of $69.69, for a total value of $120,494.01. Following the completion of the sale, the chief executive officer directly owned 925,580 shares of the company's stock, valued at $64,503,670.20. This trade represents a 0.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 188,116 shares of company stock worth $12,828,383 in the last quarter. 23.49% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Oruka Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Orion Capital Management LLC bought a new stake in Oruka Therapeutics during the 2nd quarter worth about $91,000. Royal Bank of Canada boosted its stake in shares of Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company's stock valued at $34,000 after purchasing an additional 365 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Oruka Therapeutics in the 4th quarter valued at about $37,000. PNC Financial Services Group Inc. acquired a new stake in shares of Oruka Therapeutics during the 3rd quarter worth approximately $39,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of Oruka Therapeutics during the 4th quarter worth approximately $67,000. Institutional investors own 56.44% of the company's stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source